Are you a healthcare researcher looking for European funding for your next innovative health project? If yes, then Health calls for proposals from Cluster 1 of the Horizon Europe Programme is the place to look for health-related EU funding opportunities. To make your search easier, our team has gathered a list of 10 Health calls to submit your proposal.
Why Horizon Europe and Health
Horizon Europe is the EU’s keystone funding programme for research and innovation with over €95.5 billion budget for 2021 – 2027 timeline. Horizon Europe’s ambition is to achieve the UN’s SDGs and boost the EU’s competitiveness and growth while tackling global challenges through collaborations on research and innovation.
During a health crisis, European health calls help find solutions for one of the most critical challenges of our time. The importance of health became a top European priority especially after the beginning of the 2020 pandemic, with more and more funds given towards improving the European health systems.
Health is a political priority for Europe embodied in the first strategic plan for 2021-2024 and identified in all four key strategic orientations for EU research and innovation. The Health Cluster aims to improve and protect the Health and well-being of citizens of all ages by generating new knowledge, developing innovative solutions, and integrating where relevant a gender perspective to prevent, diagnose, monitor, treat and cure diseases.
If you are interested in receiving funding for these new Health calls from Horizon Europe for research, you can submit your proposal through the EUcalls innovative platform. To make it easier for you, we have gathered 10 Health calls from Horizon Europe currently open to submit your proposal.
10 Health calls to find on EUcalls
Programme: HORIZON-HLTH-2022-TOOL-11-01
Budget: € 60,000,000
Description: The applicants should perform the clinical validation of qualified biomarkers (not limited to molecular biomarkers) that will enable the identification of appropriate patients to ensure an effective and efficient use of existing pharmaceuticals in the treatment of major diseases and conditions. The relevant biomarkers should allow providing the right medicinal product, at the right dose and the right time, according to the concept of personalised medicine, taking into account, among others, differences of sex, age, ethnicity and gender identity. This topic refers to medicines that are already on the market and not to the validation of biomarkers for the development of new medicinal products. It addresses broadly prescribed medicines for major diseases and conditions, including but not limited to cardiovascular diseases. A condition is that preliminary studies or publications have demonstrated that the pharmaceuticals considered are efficient in less than 50% of the population treated. This topic excludes cancer and rare disease treatments. The applicants should consider existing guidelines, standards and regulations, as appropriate. Synergies with relevant European Research Infrastructures are encouraged.
Deadline: 21/04/2022
Programme: HORIZON-HLTH-2022-TOOL-11-02
Budget: € 35,000,000
Description: With the emerging use of real-world data (RWD) and synthetic data by the pharmaceutical industry and medical devices industry, regulators and HTA bodies need to perform targeted validation of claims through independent analysis. The principal aim of this topic is to address the data needs of health regulatory bodies and HTA bodies across the EU, as outlined in the recently published “HMA-EMA Joint Big Data Taskforce Phase II report: ‘Evolving Data-Driven Regulation’” and its associated DARWIN (Data Analysis and Real World Interrogation Network) project.
To harness the potential of RWD and synthetic data from digital twins and advanced analytical models, and make them actionable for health regulatory decision-making and for health technology assessment, targeted research is needed on the evidentiary value of these data for a number of relevant use cases. In addition, methods need to be developed to increase the usability of such data by different stakeholder groups. Doing so will contribute to the European Health Data Space and maximise the positive impact of DARWIN in driving up the quality of evidence and decisions on the development and use of medicines and digital health innovations.
Access to and analysis of RWD and synthetic data can inform regulatory decision-making throughout the product lifecycle, namely: 1) support product development (e.g. scientific advice, PRIME),; 2) support authorisation of new medicines and digital health innovations; and 3) monitor the performance of medicines and digital health innovations on the market (effectiveness and safety). Eventually, this will put in place methods and processes that will enable continuous learning from pre-authorisation procedures and authorisation applications on the use of RWD and/or synthetic data.
Deadline: 21/04/2022
Programme: HORIZON-HLTH-2022-CARE-08-02
Budget: € 5,000,000
Description: Pre-commercial procurement (PCP) can boost innovation in health care systems, while building the capacity of providers and increasing resilience and preparedness in the context of cross-border public health emergencies. Through the competitive development of a range of breakthrough innovations for a concrete health care challenge, PCP can strengthen the security of the supply chain in the health care sector. At the same time, these instruments can support the economic recovery of the EU by providing incentives to the EU health and technology industry (especially spin-offs, start-ups and SMEs) to innovate and commercialise their products or services at a larger scale than they normally would. Fostering the development of such innovative solutions in Europe can reinforce EU strategic autonomy in strategic health technologies and lead to the creation of new markets for the EU industry, thereby contributing to EU growth, employment and competitiveness. At the same time, joint/collaborative demand-side initiatives can help create economies of scale and early adoption of innovations by the health sector. Advances in this area can help EU health care systems build resilience and respond to public health threats better than if they would act individually.
Deadline: 21/04/2022
Programme: HORIZON-HLTH-2022-CARE-08-03
Budget: € 15,000,000
Description: Public procurement of innovative solutions (PPI) can boost the wider market uptake of high impact innovations in health care systems, while building the capacity of providers and increasing resilience and preparedness in the context of cross-border public health emergencies. This can support the economic recovery of the EU by providing incentives to the EU health and technology industry (especially spin-offs, start-ups and SMEs) to innovate and by providing business opportunities to commercialise innovative products or services at a larger scale than they would normally have. By acting as early adopters of such innovative solutions, procurers can open up new growth markets for the EU industry, thereby contributing to EU growth, employment and competitiveness. At the same time, joint/collaborative demand-side initiatives can help create economies of scale and scale up the wider adoption of innovations by the health sector. Advances in this area can help EU health care systems build resilience and respond to public health threats better than if they would act individually.
Deadline: 21/04/2022
Title: Better financing models for health systems
Programme: HORIZON-HLTH-2022-CARE-08-04
Budget: € 30,000,000
Description: In 2017, spending on health care in the EU stood at 9.6% of gross domestic product, ranging from over 11% in France and Germany to less than 6% in Romania. In most countries, in-patient care services made up the bulk of health spending, while spending on pharmaceuticals also accounted for a large share of health expenditure in some countries.
Due to demographic changes in the EU with a population projected to continue ageing and higher expectations regarding provision of health care services, public health threats with relevant repercussions for society and the introduction of innovative and digital solutions to improve health care systems’ functioning, the demand for health care services as well as the budgetary pressures on health care systems are and will keep increasing.
Future models of care delivery will have to take into account both the systemic and multi-dimensional performance perspective and to look at relevant outcome and quality indicators, structure of care delivery, and knowledge base regarding optimal care delivery systems,
Deadline: 21/04/2022
Title: Enhancing cybersecurity of connected medical devices
Programme: HORIZON-HLTH-2022-IND-13-01
Budget: € 20,000,000
Description: The proposals are expected to help strengthening cybersecurity maintaining the performance of medical devices while preserving or enhancing safety, security and data confidentiality, integrity and availability. The applicants should tackle the cybersecurity issue of connected medical devices and in vitro diagnostic medical devices, in particular those that are connected to the internet, allow remote access to data and exchange private or proprietary data. They should also consider the implications of Regulation (EU) 2017/745 on medical devices and Regulation (EU) 2017/746 on in vitro diagnostic medical devices regarding qualification and classification of software. In their proposals, applicants should consider to maximise synergies with relevant initiatives, activities and programmes.
Deadline: 21/04/2022
Title: Scaling up multi-party computation, data anonymisation techniques, and synthetic data generation
Programme: HORIZON-HLTH-2022-IND-13-02
Budget: € 30,000,000
Description: It is essential to speed up and facilitate innovations in the field of data-driven tools and services for wellbeing, prevention, diagnosis, treatment and follow-up of care, among others. However, limited access by developers to health data and secure testing environments hinder the development of innovative data-driven digital health products and services.
Therefore, the proposals are expected to scale up multi-party computation, data anonymisation techniques and synthetic data generation. To ensure privacy, the data analytics should be conducted in a distributed way among processors that grant third parties access to analysis outcomes but not to the underlying data. The developers should have access to distributed testing data sources and cloud and computing resources at large scale, with a view to improving the speed and robustness of multi-party computation solutions for innovators. The aim is to allow secure GDPR-compliant data processing for research, and clinical purposes.
Deadline: 21/04/2022
Title: New pricing and payment models for cost-effective and affordable health innovations
Programme: HORIZON-HLTH-2022-IND-13-03
Budget: € 15,000,000
Description: Applicants are requested to propose new value-based pricing and reimbursement models that can help ensure equitable access to effective, efficient, affordable, and sustainable health technologies, including medicines, while supporting innovation and industrial competitiveness. The research should tackle the issue globally and be based on a multidisciplinary approach combining economic science, political science and sociology. The proposals should not be limited to the study of cost-effectiveness analyses and thresholds in decision-making. They should also address long term intended and unintended consequences of pricing and reimbursement decisions. Moreover, they should consider the potential limitation of no-coverage decision for products with high budgetary impact. Applicant consortia should include regulators and public entities that are in charge of attributing value tags to health technologies, negotiating with health technology manufacturers and/or reimbursing medical costs. Differences between public and private sectors could be considered, as appropriate. Proposals should also consider citizens engagement and dialogue, for seeking wider input and support, and could encourage other social innovation approaches.
Deadline: 21/04/2022
Title: Setting up a European Smart Health Innovation Hub
Programme: HORIZON-HLTH-2022-IND-13-04
Budget: € 2,000,000
Description: The EU has supported innovation of digital tools for better and more personalised treatments and self-monitoring of citizens and patients throughout Europe. However, adoption and deployment of digital health solutions in practice, both in the public health system and by private players remains low.
Building on the recommendations from the report of the Strategic Forum for Important Projects of Common European Interest, coordination and support is needed to: i) create a pan-European operational network as a mechanism (a European Smart Health Innovation Hub) that can assess and promote Smart Health initiatives; ii) stimulate the demand-side and the uptake of Smart Health products and services; and iii) support the development of Smart Health products and services.
Deadline: 21/04/2022
Title: Methods for assessing health-related costs of environmental stressors
Programme: HORIZON-HLTH-2022-ENVHLTH-04-01
Budget: € 20,000,000
Description: Policy-makers face challenges when devising pollution mitigation measures and having to assess the health costs emerging from life-long exposures to environmental stressors or the benefits from clean environments. Deaths and disabilities resulting from pollution carry a quantifiable economic cost to society, but there are significant uncertainties in the cost estimates methodologies. There is also paucity of data to evaluate the economic benefits of clean environments.
Impact Pathway Analysis and Health Impact Assessment (HIA) are methodologies, which can be useful in linking scientific knowledge with environmental economics for informing policy action in diverse sectors such as transport, energy, chemicals, occupational health etc.
Proposed research activities should mainly aim to improve the calculation of the socio-economic costs (and/or benefits) of health impacts during the life-course associated to environmental stressors, or combinations of these, advance methodological approaches and foster their acceptance as common good practice.
Deadline: 21/04/2022
Title: Personalised blueprint of chronic inflammation in health-to-disease transition
Programme: HORIZON-HLTH-2022-STAYHLTH-02-01
Budget: € 7,000,000
Description: Personalised approaches for disease prevention seek to determine the predisposition to disease and deliver timely and targeted prevention measures. Understanding the risk factors that trigger the health-to-disease transition is essential for delivering personalized prevention measures or reducing the burden of chronic diseases.
A large body of clinical evidence has accumulated over the past decade demonstrating that chronic inflammation is a process implicated in chronic diseases/disorders. Inflammatory response is a physiological process helping the body to heal against harmful entities, but when dysregulated it could lead to unresolved chronic local or systemic inflammation. The later in combination with the person’s genotype, phenotype, medical history, nutritional and well-being status, life-style and/or occupational/environmental/life stressors is likely to be involved in driving the health-to-disease transition, leading to the onset of chronic diseases.
Deadline: 21/04/2022
Title: European partnership on transforming health and care systems
Programme: HORIZON-HLTH-2022-CARE-10-01
Budget: € 100,000,000
Description: For many reasons (demographic changes, technological progress, fiscal constraints, public health emergencies etc.) the European health and care systems are expected to be subject to severe stress. In particular, the COVID-19 pandemic has highlighted existing structural weaknesses in health and care systems, and emphasised areas where not enough effort, planning and resources had been directed to. In addition, rapid technological and societal evolutions call for urgent responses to increasing demands and expectations from citizens. There is a need to accelerate the transition towards more efficient, sustainable, resilient, innovative and accessible health and care systems in Europe. To this end, the creation of a research and innovation (R&I) partnership with a focus on health and care systems’ transformation represents a unique strategic opportunity to bring together stakeholders, create synergies, coordinate R&I actions, facilitate the digitization of health and care services and support the transformation of health and care systems with innovative solutions driven by knowledge and evidence. The partnership should build on knowledge gained from initiatives taken under Horizon 2020 (TO-REACH, Active and Assisted Living programme (AAL), Joint Programming Initiative More Years, Better, Lives (JPI MYBL), European Innovation partnership (EIP-AHA), ICPerMed, etc.). In order to increase the likelihood of successful system transformation, the partnership will facilitate the exchange of information and good practices among countries, provide robust guidance and tools, network institutional stakeholders and involve regional ecosystems. It will stimulate service, policy and organisational innovations, as well as the integration of biomedical and technological innovations for the benefit of the European citizens and the European industry. The development of new products is beyond the scope of this Partnership. By laying the ground for the transformation of the health and care systems, the partnership will contribute to the transition of Europe to more sustainable development and address emerging threats raised by environmental changes and globalisation.
Deadline: 21/04/2022
By joining the EUcalls community you can find all the above Health Calls from Horizon Europe for free on our innovative platform. You can also opt-in for one of our premium plans to access additional features that can help you throughout your EU funding journey. Our platform offers a streamlined process of locating the perfect European calls for you and finding the right partners for your consortia.
To convince you for the quality of our services, you can become a premium user for free using a 30-day trial.
